Free Trial
NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

$6.75
-0.69 (-9.27%)
(As of 05/24/2024 08:49 PM ET)
Today's Range
$6.63
$7.36
50-Day Range
$6.31
$9.31
52-Week Range
$3.16
$10.13
Volume
6.58 million shs
Average Volume
5.98 million shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.81

Ardelyx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.11 Rating Score
Upside/​Downside
89.8% Upside
$12.81 Price Target
Short Interest
Bearish
15.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
0.40mentions of Ardelyx in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$3.16 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.36) to $0.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

117th out of 922 stocks

Pharmaceutical Preparations Industry

45th out of 428 stocks

ARDX stock logo

About Ardelyx Stock (NASDAQ:ARDX)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Stock Price History

ARDX Stock News Headlines

Ardelyx (NASDAQ:ARDX) Stock Rating Reaffirmed by Piper Sandler
Ardelyx (NASDAQ:ARDX) Shares Down 3.6%
Wedbush Reaffirms Outperform Rating for Ardelyx (NASDAQ:ARDX)
Ardelyx slips as commercial chief departs
Latest News for Ardelyx Stock (NASDAQ:ARDX)
Ardelyx (NASDAQ:ARDX) Lowered to "Sell" at StockNews.com
The 3 Best Penny Stocks to Buy in May 2024
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx: Strong Execution, Fairly Valued
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
5/27/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARDX
Employees
267
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$12.81
High Stock Price Target
$15.00
Low Stock Price Target
$8.50
Potential Upside/Downside
+89.8%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$-66,070,000.00
Pretax Margin
-40.95%

Debt

Sales & Book Value

Annual Sales
$124.46 million
Book Value
$0.65 per share

Miscellaneous

Free Float
219,902,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
0.87

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

ARDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price target for 2024?

9 brokerages have issued 12-month price objectives for Ardelyx's shares. Their ARDX share price targets range from $8.50 to $15.00. On average, they predict the company's stock price to reach $12.81 in the next twelve months. This suggests a possible upside of 89.8% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2024?

Ardelyx's stock was trading at $6.20 at the beginning of the year. Since then, ARDX shares have increased by 8.9% and is now trading at $6.75.
View the best growth stocks for 2024 here
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) released its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biopharmaceutical company had revenue of $46 million for the quarter, compared to the consensus estimate of $36.40 million. Ardelyx had a negative net margin of 41.36% and a negative trailing twelve-month return on equity of 41.65%. The firm's revenue for the quarter was up 303.5% compared to the same quarter last year. During the same period last year, the company earned ($0.13) EPS.

What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.47%), Vanguard Group Inc. (5.72%), Price T Rowe Associates Inc. MD (1.68%), Redmile Group LLC (0.94%), Jane Street Group LLC (0.00%) and BNP Paribas Financial Markets (0.25%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDX) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners